Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 363 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Child Disruptive Behavior Disorders Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Mental Health and School Performance in Urban Eighth Graders

NCT03906682
View directory record Official record
Conditions
Depressive Symptoms, Trauma, Psychological, Disruptive Behavior
Interventions
RAP Club, Healthy Topics
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

NCT00418262
View directory record Official record
Conditions
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Atomoxetine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

NCT03006367
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Maitland, Florida • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 1 Interventional

Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies

NCT01073176
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
TEAMS (Training Attention Executive and Motor Skills)
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
4 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders

NCT03730194
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
Interventions
Melatonin, Bedtime Bank
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs

NCT01808066
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
Interventions
Groundskeeper
Device
Lead sponsor
CogCubed, Corp
Industry
Eligibility
5 Years to 12 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 1 Interventional

Mental Health Services for Foster and Adopted Children

NCT00056303
View directory record Official record
Conditions
Problem Behaviors, Attention Deficit Hyperactivity Disorder, Depression
Interventions
Attachment and Biobehavioral Catch-up, Developmental Education for Families
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
20 Months to 36 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 6, 2026, 3:27 AM EDT
Completed No phase listed Observational

Assessment of Attentional Functioning in Children With HIV-1 Infection

NCT00001497
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, HIV Infections, Paralysis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Evaluation of a Video-Based Media Series to Promote Effective Parenting

NCT00611832
View directory record Official record
Conditions
Childhood Disruptive Behavior Problems
Interventions
Triple P Media Series -- Standard "Information-Only" version, Triple P Media Series -- Enhanced "Behavior Activation" version
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
20 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

NCT03247530
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 100mg SPN-812, 200mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

NCT02402166
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newport Beach, California • Baltimore, Maryland • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 6, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

NCT03638466
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions
Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo
Diagnostic Test · Behavioral · Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Lakeland, Florida • Maitland, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

NCT00857220
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carson, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders

NCT00402857
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Interventions
Incredible Years Program
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
22 Months to 38 Months
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
9
States / cities
Chelsea, Massachusetts • Dorchester, Massachusetts • Jamaica Plain, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 6, 2026, 3:27 AM EDT
Completed No phase listed Observational

Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers

NCT00026546
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 6, 2026, 3:27 AM EDT
Active, not recruiting Phase 4 Interventional

Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

NCT05469386
View directory record Official record
Conditions
ADHD
Interventions
Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
Drug · Behavioral
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 6, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

NCT00626236
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Interventions
SPN-810
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Bradenton, Florida • Gainesville, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 6, 2026, 3:27 AM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 6, 2026, 3:27 AM EDT